Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gemfibrozil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA known ✓ | Q07869 | 9/20 | 0.97 |
| ▸ | TSHR | P16473 | 3/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.97 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.97 |
| ▸ | TTR | P02766 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.97 |
| ▸ | PPARG | P37231 | 1/20 | 0.97 |
| ▸ | HTR2B | P41595 | 1/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.97 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.97 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.97 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.97 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.58 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.56 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gemfibrozil SCHEMBL29398115 | 0.99 | PPARA (1.00) | PPARATSHRCYP2C9CYP2C8TTR | |
| Gemfibrozil SCHEMBL20770039 | 0.99 | PPARA (1.00) | PPARATSHRCYP2C9CYP2C8TTR | |
| Gemfibrozil SCHEMBL4813 | 0.99 | PPARA (1.00) | PPARATSHRCYP2C9CYP2C8TTR | |
| Gemfibrozil SCHEMBL1880616 | 0.99 | PPARA (1.00) | PPARATSHRCYP2C9CYP2C8TTR | |
| Gemfibrozil SCHEMBL21052128 | 0.97 | PPARA (0.97) | PPARATSHRCYP2C9CYP2C8TTR | |
| Gemfibrozil SCHEMBL10542601 | 0.97 | PPARA (0.97) | PPARATSHRCYP2C9CYP2C8TTR | |
| Gemfibrozil SCHEMBL6033508 | 0.93 | PPARA (0.90) | PPARATSHRCYP2C9CYP2C8TTR | |
| SCHEMBL21992001 | 0.91 | PPARA (0.86) | PPARATSHRCYP2C9CYP2C8TTR | |
| SCHEMBL12690944 | 0.87 | PPARA (0.79) | PPARATSHRCYP2C9CYP2C8TTR | |
| SCHEMBL9481043 | 0.87 | PPARA (0.79) | PPARATSHRCYP2C9CYP2C8TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111808011-B | High penetration composition and its application | 泰飞尔生物医药(苏州)有限公司 | 2024-02-27 | — | — | CN | disclosed |
| US-20230233516-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | TECHFIELDS PHARMA CO., LTD (CN) | 2023-07-27 | — | — | US | disclosed |
| US-11541029-B2 | High penetration compositions and their applications | TECHFIELDS PHARMA CO., LTD. (CN) | 2023-01-03 | — | — | US | disclosed |
| CN-113636965-A | High penetration composition and application thereof | 于崇曦 | 2021-11-12 | — | — | CN | disclosed |
| CN-107320732-B | High penetration composition and application thereof | 于崇曦 | 2021-09-07 | — | — | CN | disclosed |
| CN-108191846-B | High penetration composition and application thereof | 于崇曦 | 2021-08-20 | — | — | CN | disclosed |
| CN-111808011-A | High penetration composition and application thereof | 于崇曦 | 2020-10-23 | — | — | CN | disclosed |
| US-8470805-B2 | Processes for preparing piperazinium salts of KMUP and use thereof | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2013-06-25 | — | — | US | disclosed |
| WO-2012031445-A1 | PROCESSES FOR PREPARING PIPERAZINIUM SALTS OF KMUP AND USE THEREOF | KAOHSIUNG MEDICAL UNIVERSITY (CN) | 2012-03-15 | — | — | WO | disclosed |
| US-20110269689-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | PREMIER RESEARCH INTERNATIONAL, LLC | 2011-11-03 | — | — | US | disclosed |
| EP-2370406-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | Yu, Chongxi (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20110136767-A1 | PROCESSES FOR PREPARING PIPERAZINIUM SALTS OF KMUP AND USE THEREOF | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2011-06-09 | — | — | US | disclosed |
| WO-2010065936-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | YU CHONGXI (US) | 2010-06-10 | — | — | WO | disclosed |
| CN-101723823-A | Gemfibrozil composite method | SHANGHAI ECUST BIOMEDICINE CO | 2010-06-09 | — | — | CN | disclosed |
| EP-0699177-A1 | A PROCESS FOR THE PREPARATION OF GEMFIBROZIL | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1996-03-06 | — | — | EP | disclosed |
| WO-1994027948-A1 | A PROCESS FOR THE PREPARATION OF GEMFIBROZIL | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269689-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | SLC19A1, HIRA, SLC43A1 | PPARA 788/4885TSHR 4827/4885CYP2C9 133/4885 |
| US-20110136767-A1 | PROCESSES FOR PREPARING PIPERAZINIUM SALTS OF KMUP AND USE THEREOF | U2SURP, RRP15, KYNU | PPARA 2092/4885TSHR 767/4885CYP2C9 1898/4885 |
| US-11541029-B2 | High penetration compositions and their applications | SLC19A1, HIRA, SLC43A1 | PPARA 788/4885TSHR 4827/4885CYP2C9 133/4885 |
| US-20230233516-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | SLC5A7, SLC19A1, SLC43A1 | PPARA 777/4885TSHR 4760/4885CYP2C9 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.